Suiseng Diff/A Suspension for Injection for Pigs

Land: Storbritannien

Språk: engelska

Källa: VMD (Veterinary Medicines Directorate)

Aktiva substanser:

Clostridioides difficile, Clostridium perfringens

Tillgänglig från:

Laboratorios Hipra SA

ATC-kod:

QI09AB12

INN (International namn):

Clostridioides difficile, Clostridium perfringens

Läkemedelsform:

Suspension for injection

Receptbelagda typ:

POM-V - Prescription Only Medicine – Veterinarian

Terapeutisk grupp:

Pigs

Terapiområde:

Inactivated Bacterial Vaccine

Bemyndigande status:

Authorized

Tillstånd datum:

2021-11-24

Produktens egenskaper

Revised: August 2022
AN: 00754/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Suiseng Diff/A suspension for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
ACTIVE SUBSTANCES:
_Clostridioides difficile_, toxoid A (TcdA)
≥ 1.60 RP*
_Clostridioides difficile_, toxoid B (TcdB)
≥ 1. 65 RP*
_Clostridium perfringens_ type A, α-toxoid
≥ 1.34 RP*
* RP: Relative Potency determined by ELISA
ADJUVANTS:
Aluminium hydroxide gel
0.6 g
Ginseng extract (equivalent to ginsenosides)
DEAE-dextran
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Yellowish-white suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (pregnant sows and gilts).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the passive immunisation of neonatal piglets by means of the
active
immunisation of breeding sows and gilts:
-
to prevent mortality and reduce clinical signs and macroscopic lesions
caused by
_C. difficile, _toxins A and B_._
-
to reduce clinical signs and macroscopic lesions caused by _C.
perfringens_ type
A, α-toxin.
The reduction of the occurrence of neonatal diarrhoea has been
demonstrated under
field conditions.
Onset of immunity:
Protection was demonstrated in suckling piglets on the first day of
life in challenge
studies.
Revised: August 2022
AN: 00754/2022
Page 2 of 5
Duration of immunity:
Neutralising protective antibodies transferred via colostrum to the
piglets were
present up to 28 days after birth in the majority of the piglets.
4.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance, to
the adjuvant or to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
Protection of piglets is achieved by colostrum intake. Therefore, care
should be taken
to ensure that each piglet ingests a sufficient quantity of colostrum
within the first
hours of life.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for